Brief: Medicenna Doses First Patient in MDNA11 Phase 1/2 ABILITY Study
14/09/2021 13:55
Sept 14 (Reuters) - Medicenna Therapeutics Corp MDNA.TO :
* MEDICENNA DOSES FIRST PATIENT IN MDNA11 PHASE 1/2 ABILITY
STUDY
* MEDICENNA THERAPEUTICS - PRELIMINARY UPDATE ON SAFETY,
PK/PD,
AND BIOMARKER DATA EXPECTED BY YEAR-END 2021
* MEDICENNA THERAPEUTICS CORP - PRELIMINARY EFFICACY
READOUTS FROM
STUDY EXPECTED OVER COURSE OF 2022
Source text for Eikon: ID:nGNX7Qq0kJ
Further company coverage: MDNA.TO
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Medicenna Therapeutics
See all newsBrief: Medicenna Therapeutics - Announces Two New U.S. Patents And One Allowed U.S. Patent Application
Brief: Medicenna Announces The Finalization Of The Terms Of Its Public Offering Of Securities
Brief: Medicenna Announces The Launch Of A Marketed Public Offering Of Securities
Brief: Medicenna Therapeutics Appoints Dr. Nageatte Ibrahim As Chief Medical Officer
Brief: Medicenna Therapeutics Reports Third Quarter Fiscal 2026 Financial Results